Overview
- HRSA now recommends a primary high‑risk HPV test every five years for average‑risk people ages 30–65, with Pap testing every three years retained for ages 21–29 and co‑testing allowed at five‑year intervals.
- Self‑collected vaginal samples are permitted using FDA‑approved tests in clinics or at home, with the at‑home option available by prescription and at least one kit already authorized.
- Most private insurers must cover screening and the necessary follow‑up—such as cytology, biopsy and lab work—without cost‑sharing starting Jan. 1, 2027.
- The guidance targets gaps in screening uptake to reduce cervical cancer burden, while excluding higher‑risk groups like those with HIV, other immunocompromising conditions, in‑utero DES exposure, or recent CIN2+ treatment.
- The American Cancer Society’s December update is largely aligned but starts screening at 25 and recommends a three‑year interval for self‑collected tests as experts also stress systems to ensure timely follow‑up after abnormal results.